Don't miss

Replay


LATEST SHOWS

EYE ON AFRICA

Amnesty warns of 'horrific' violence in Cameroon's anglophone regions

Read more

MEDIAWATCH

Maduro: Let them eat steak

Read more

THE DEBATE

Syria: Russia and Israel seek to avoid spiral over plane downing

Read more

FOCUS

Mexico's seaweed invasion: Disaster or opportunity?

Read more

ENCORE!

Joaquin Phoenix: 'Jacques Audiard is unique, even among French directors'

Read more

ACCESS ASIA

Iwao Hakamada, the Japanese boxer still fighting... for his life

Read more

IN THE PRESS

Should supermodels' catwalk strut be protected by copyright?

Read more

PERSPECTIVE

Child development: Inside a child's incredible brain

Read more

BUSINESS DAILY

US hits China with trade tariffs on $200bn of goods

Read more

US approves first marijuana-derived drug

© AFP/File | Cannabidiol, or CBD, is derived from cannabis plants, but does not cause users to get high The company procudes high cannabidiol (CBD) content cannabis with THC (psychoactive component) content below the Swiss legal limit. KannaSwiss sell medicinal oil and flowers to smoke.

WASHINGTON (AFP) - 

US regulators on Monday approved the first marijuana-derived drug ever to hit the US market, Epidiolex, which will be used to treat two rare and severe forms of childhood epilepsy.

Epidiolex uses purified cannabidiol, or CBD, which is one of more than 80 active compounds in the cannabis plant.

"This is an important medical advance," said US Food and Drug Administration Commissioner Scott Gottlieb.

"But it's also important to note that this is not an approval of marijuana or all of its components. This is the approval of one specific CBD medication for a specific use," he added.

"And it was based on well-controlled clinical trials evaluating the use of this compound in the treatment of a specific condition."

The drug is approved for use against Lennox-Gastaut syndrome and Dravet syndrome in patients two years of age and older, the FDA said.

Both forms of epilepsy cause severe seizures.

An advisory panel to the FDA recommended in April that the drug be approved.

The FDA is not required to follow the advisory panel's advice but usually does.

CBD does not cause intoxication or euphoria. That so-called "high" comes from a different compound in marijuana, known as tetrahydrocannabinol (THC).

© 2018 AFP